Jun 2026 (Q2 FY26) — Aug 5, 2026
GRAIL Q2 FY26 — Strong Galleri Volume Growth and FDA AdCom Anticipation
Read the full callGRAIL (GRAL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
GRAIL earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 44.7 | +25.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -388.9 | +58.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -110 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$122.42 +3.91% · +$4.61
Performance +56.9% 1Y
1Y: $78 on 17 Oct 2025 → $122.42. High $154.08 (5 Oct 2026), low $43.03 (23 Feb 2026).
- Previous close
- $117.81
- 52-week range
- $43.03 – $154.08
- One year
- +33.28%
Overview
- Symbol
- GRAL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
GRAIL earnings calls (GRAL)
Financials
What the filings say
Net profit, year on year: +3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 38 | 32 | 36 | 36 | 44 | 41 | 45 |
| Expenses | 212 | 175 | 185 | 194 | 161 | 168 | 177 | 218 |
| Operating profit | -184 | -137 | -154 | -159 | -125 | -124 | -136 | -174 |
| Operating margin | −640.5% | −358.0% | −482.5% | −446.9% | −346.2% | −285.4% | −332.9% | −388.9% |
| Other income | 11 | 10 | 7 | 6 | 7 | 8 | 8 | 7 |
| Profit before tax | -172 | -127 | -146 | -153 | -119 | -117 | -128 | -167 |
| Tax rate | 27.1% | 23.6% | 27.5% | 25.4% | 25.1% | 14.9% | 26.9% | 33.9% |
| Net profit | -126 | -97 | -106 | -114 | -89 | -99 | -93 | -110 |
| EPS ($ per share) | -3.94 | — | -3.10 | -3.18 | -2.46 | — | -2.29 | -2.56 |
| Line item | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 |
| Reserves | — | -7,776 | -9,803 | -10,212 |
| Total liabilities | — | 268 | 480 | 344 |
| Fixed assets | — | 85 | 69 | 52 |
| Total assets | — | 3,914 | 2,983 | 2,922 |
| Line item | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -561 | -596 | -577 | -299 |
| Cash from investing | -23 | -13 | -551 | -85 |
| Cash from financing | 605 | 464 | 1,244 | 423 |
| Net cash flow | 20 | -145 | 116 | 39 |
| Capital expenditure | -23 | -13 | -5 | -1 |
| Free cash flow | -584 | -609 | -582 | -300 |
Insider filings
69 filings between Nov 17, 2025 and Oct 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$117.98M
48 sales by 5 insiders
40% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ILLUMINA, INC. | — | $79.85M | Nov 17, 2025 |
| Ofman Joshua J. | — | $14.58M | Oct 15, 2026 |
| RAGUSA ROBERT P | — | $12.27M | Apr 8, 2026 |
| Freidin Aaron | — | $10.05M | Oct 5, 2026 |
| Partridge Andrew John | — | $1.24M | Oct 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 15, 2026 | SUMME GREGORY L Director | Award | 237 | $32.1K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 3,400 | $460.5K |
| Oct 15, 2026 | CHASE WILLIAM J Director | Award | 153 | $20.7K |
| Oct 15, 2026 | MIZELL STEVEN Director | Award | 148 | $20.0K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 1,000 | $134.4K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 7,052 | $964.9K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 400 | $53.2K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 6,034 | $830.5K |
| Oct 15, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 2,114 | $293.4K |
| Oct 5, 2026 | Freidin Aaron Chief Financial Officer | Sale | 23,619 | $3.46M |
| Oct 5, 2026 | Partridge Andrew John Chief Growth Officer | Sale | 7,873 | $1.15M |
| Sep 21, 2026 | Freidin Aaron Chief Financial Officer | Sale 10b5-1 plan | 1,800 | $169.0K |
| Sep 21, 2026 | Freidin Aaron Chief Financial Officer | Sale 10b5-1 plan | 1,779 | $164.1K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 6,200 | $597.9K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 10,000 | $1.10M |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 37,752 | $3.59M |
| Sep 21, 2026 | Freidin Aaron Chief Financial Officer | Sale 10b5-1 plan | 521 | $49.5K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 1,400 | $137.0K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 2,100 | $211.4K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 2,125 | $196.2K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Option exercise 10b5-1 plan | 26,452 | $370.3K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 1,454 | $136.1K |
| Sep 21, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 421 | $42.0K |
| Aug 27, 2026 | Freidin Aaron Chief Financial Officer | Sale 10b5-1 plan | 7,900 | $671.6K |
| Aug 27, 2026 | Ofman Joshua J. Chief Executive Officer | Sale 10b5-1 plan | 5,000 | $425.1K |
| Jul 15, 2026 | CHASE WILLIAM J Director | Award | 276 | $20.5K |
| Jul 15, 2026 | MIZELL STEVEN Director | Award | 268 | $19.9K |
| Jul 15, 2026 | SUMME GREGORY L Director | Award | 427 | $31.8K |
| Jun 18, 2026 | CHASE WILLIAM J Director | Award | 5,491 | $350.0K |
| Jun 18, 2026 | MIZELL STEVEN Director | Award | 5,491 | $350.0K |
| Jun 18, 2026 | SUMME GREGORY L Director | Award | 5,491 | $350.0K |
| Jun 18, 2026 | Krevans Sarah Director | Award | 5,491 | $350.0K |
| Jun 4, 2026 | Partridge Andrew John Chief Growth Officer | Sale | 1,491 | $91.1K |
| Jun 3, 2026 | Ofman Joshua J. Chief Executive Officer | Award | 3,154 | $192.8K |
| Jun 1, 2026 | Ofman Joshua J. Chief Executive Officer | Award | 27,901 | $1.80M |
| Apr 15, 2026 | CHASE WILLIAM J Director | Award | 408 | $20.3K |
| Apr 15, 2026 | SUMME GREGORY L Director | Award | 631 | $31.4K |
| Apr 15, 2026 | MIZELL STEVEN Director | Award | 396 | $19.7K |
| Apr 8, 2026 | RAGUSA ROBERT P Chief Executive Officer | Sale | 123,502 | $6.16M |
| Apr 8, 2026 | Freidin Aaron Chief Financial Officer | Sale | 45,806 | $2.29M |
| Apr 8, 2026 | Ofman Joshua J. President | Sale | 61,665 | $3.08M |
| Mar 9, 2026 | Freidin Aaron Chief Financial Officer | Sale | 85 | $4.0K |
| Mar 9, 2026 | Freidin Aaron Chief Financial Officer | Sale | 2,407 | $115.4K |
| Mar 9, 2026 | Ofman Joshua J. President | Sale | 101 | $4.7K |
| Mar 9, 2026 | RAGUSA ROBERT P Chief Executive Officer | Sale | 7,203 | $345.2K |
| Mar 9, 2026 | Ofman Joshua J. President | Sale | 2,836 | $135.9K |
| Mar 9, 2026 | RAGUSA ROBERT P Chief Executive Officer | Sale | 258 | $12.1K |
| Mar 5, 2026 | RAGUSA ROBERT P Chief Executive Officer | Sale | 980 | $51.9K |
| Mar 5, 2026 | Freidin Aaron Chief Financial Officer | Sale | 655 | $34.7K |
| Mar 5, 2026 | Ofman Joshua J. President | Sale | 690 | $36.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GRAIL, Inc.
Free account. Everything above stays public.
Write why you follow GRAIL, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading